Biora Therapeutics (BIOR) Competitors $1.62 +0.01 (+0.31%) (As of 11:20 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrends BIOR vs. CNTG, RNLX, MEIP, RNXT, KALA, BLRX, DARE, PLUR, LSB, and TNXPShould you be buying Biora Therapeutics stock or one of its competitors? The main competitors of Biora Therapeutics include Centogene (CNTG), Renalytix (RNLX), MEI Pharma (MEIP), RenovoRx (RNXT), KALA BIO (KALA), BioLineRx (BLRX), Daré Bioscience (DARE), Pluri (PLUR), Lakeshore Biopharma (LSB), and Tonix Pharmaceuticals (TNXP). Biora Therapeutics vs. Centogene Renalytix MEI Pharma RenovoRx KALA BIO BioLineRx Daré Bioscience Pluri Lakeshore Biopharma Tonix Pharmaceuticals Biora Therapeutics (NASDAQ:BIOR) and Centogene (NASDAQ:CNTG) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends. Do analysts rate BIOR or CNTG? Biora Therapeutics presently has a consensus price target of $23.00, suggesting a potential upside of 1,315.38%. Given Biora Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Biora Therapeutics is more favorable than Centogene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biora Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Centogene 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community prefer BIOR or CNTG? Centogene received 32 more outperform votes than Biora Therapeutics when rated by MarketBeat users. However, 80.00% of users gave Biora Therapeutics an outperform vote while only 64.52% of users gave Centogene an outperform vote. CompanyUnderperformOutperformBiora TherapeuticsOutperform Votes880.00% Underperform Votes220.00% CentogeneOutperform Votes4064.52% Underperform Votes2235.48% Does the media prefer BIOR or CNTG? In the previous week, Biora Therapeutics had 7 more articles in the media than Centogene. MarketBeat recorded 7 mentions for Biora Therapeutics and 0 mentions for Centogene. Centogene's average media sentiment score of 0.00 beat Biora Therapeutics' score of -0.29 indicating that Centogene is being referred to more favorably in the news media. Company Overall Sentiment Biora Therapeutics Neutral Centogene Neutral Is BIOR or CNTG more profitable? Company Net Margins Return on Equity Return on Assets Biora TherapeuticsN/A N/A -332.47% Centogene N/A N/A N/A Which has stronger valuation and earnings, BIOR or CNTG? Centogene has higher revenue and earnings than Biora Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiora TherapeuticsN/AN/A-$124.11M-$13.04-0.12Centogene$48.54M0.00-$38.58MN/AN/A Do insiders and institutionals have more ownership in BIOR or CNTG? 43.7% of Biora Therapeutics shares are owned by institutional investors. Comparatively, 9.9% of Centogene shares are owned by institutional investors. 51.1% of Biora Therapeutics shares are owned by insiders. Comparatively, 1.9% of Centogene shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, BIOR or CNTG? Biora Therapeutics has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Centogene has a beta of -0.67, suggesting that its stock price is 167% less volatile than the S&P 500. SummaryBiora Therapeutics beats Centogene on 8 of the 13 factors compared between the two stocks. Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get Biora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BIOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIOR vs. The Competition Export to ExcelMetricBiora TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.35M$6.48B$5.08B$8.80BDividend YieldN/A8.11%5.02%4.07%P/E Ratio-0.124.9791.2813.60Price / SalesN/A371.451,226.2187.40Price / CashN/A52.5939.4536.27Price / Book-0.0710.306.906.33Net Income-$124.11M$153.61M$118.83M$225.93M7 Day Performance-31.72%-1.73%-1.92%-0.96%1 Month Performance-64.21%-7.26%-3.75%1.06%1 Year Performance-87.78%31.10%31.37%26.59% Biora Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIORBiora Therapeutics2.5866 of 5 stars$1.63+0.3%$23.00+1,315.4%-87.9%$7.35MN/A-0.12120Analyst ForecastCNTGCentogeneN/AN/AN/AN/A$8.80M$48.54M0.00810Gap UpHigh Trading VolumeRNLXRenalytixN/A$0.21+5.7%$3.00+1,348.6%-62.3%$17.18M$2.29M-0.53100Gap UpMEIPMEI Pharma4.1926 of 5 stars$2.77-1.1%$7.00+152.7%-50.5%$18.45M$65.30M-0.40100RNXTRenovoRx2.6223 of 5 stars$1.20+0.8%$6.13+410.4%+98.7%$28.80MN/A-2.126News CoveragePositive NewsKALAKALA BIO4.0824 of 5 stars$6.20-3.6%$15.00+141.9%+7.8%$28.58M$3.89M0.0030BLRXBioLineRx1.9751 of 5 stars$0.36-34.6%$21.00+5,789.0%-67.9%$28.51M$4.80M0.0040News CoverageGap DownHigh Trading VolumeDAREDaré Bioscience2.203 of 5 stars$3.18flat$24.00+654.7%-23.9%$27.67M$2.81M-5.3830PLURPluri0.1524 of 5 stars$4.96-2.0%N/A+11.5%$27.58M$330,000.00-0.82150LSBLakeshore Biopharma0.2075 of 5 stars$2.94+12.2%N/AN/A$27.37M$80.82M0.00773Gap DownTNXPTonix Pharmaceuticals2.9424 of 5 stars$0.20+4.7%$53.50+26,797.9%-98.8%$27.30M$7.77M0.00103Analyst ForecastGap Down Related Companies and Tools Related Companies Centogene Competitors Renalytix Competitors MEI Pharma Competitors RenovoRx Competitors KALA BIO Competitors BioLineRx Competitors Daré Bioscience Competitors Pluri Competitors Lakeshore Biopharma Competitors Tonix Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BIOR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BIOR Stock Alerts